Original title: Topology-Informed Survival Analysis of Breast Cancer Patients Using the Mapper Algorithm
Emmanuel Kibisi, Olakunle Abawonse, Donald Woukeng · July 2026
Standard breast cancer categories can miss important clues about patient survival. Researchers addressed this by applying a math tool called the Mapper algorithmA tool that turns complex, high-dimensional data into a simplified network of connected clusters. to gene expression dataMeasurements showing how active each gene is in a patient's tumor cells.. Gene expression is the activity level of different genes in tumor cells. The Mapper tool maps this complex data into a geometric network of patient groups. Patients falling into high-risk spots on this network had significantly worse survival. Tumors with fast cell growth patterns also led to worse outcomes overall, but treatment shrank this survival difference. Surprisingly, the tool found patients who defied standard expectations. It identified a Basal-likeA breast cancer subtype usually considered aggressive and harder to treat. subgroup with unexpectedly good survival tied to a treatment-responsive gene pattern. Testing on unseen patients confirmed this network shape adds valuable survival clues beyond standard methods.
Imagine sorting a box of mixed screws by size. You group them roughly into small, medium, and large, and assume each pile will hold the same. But a few large screws are made of a different alloy, so they fail where the others don't—and the size sorting hides them completely. In this paper, breast cancer patients are arranged into a network from their molecular measurements, and the shape of that network catches hidden subgroups that the standard labels miss.
Doctors classify breast cancer into subtypes, yet patients in the same subtype can fare very differently. This work shows that mapping gene activity as a geometric network finds hidden groups—including a Basal-like subgroup that did surprisingly well—so prognosis and treatment might be matched more precisely than current categories allow.
The abstract doesn't say whether the risk groups were tested in an independent external cohort; validation is described only as training and testing on unseen patients from the same TCGA-BRCA set. It also doesn't specify which treatments narrowed the survival gap across proliferation groups, or whether the newly identified Basal-like gene signature would change clinical decisions.
Ask anything about this paper. Answers come from its abstract, and say so when the abstract doesn't cover your question.
Topology-Informed Survival Analysis of Breast Cancer Patients Using the Mapper Algorithm — Emmanuel Kibisi, Olakunle Abawonse, Donald Woukeng
Abstract licence: CC0
Explanation generated by Synthesis from the abstract — it is not the original paper. This is a preprint, so it hasn't necessarily been peer reviewed.